Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy

Acta Dermato-Venereologica

Volumn 83, Issue 4, 2003, Pages 241-248

  Jappe, Uta ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Acne therapy; Acne vulgaris; Mitogen; Propionibacterium acnes

Indexed keywords

ADAPALENE; ANTIGEN; ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CLINDAMYCIN; CORTICOSTEROID; CYPROTERONE ACETATE; CYTOKINE; ERYTHROMYCIN; ESTRADIOL; HYDROCORTISONE; ISOTRETINOIN; LINOLEIC ACID; LITHIUM; MINOCYCLINE; MITOGENIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRASTERONE SULFATE; PROLACTIN; RETINOIC ACID; RETINOID; RETINOL DERIVATIVE; ROXITHROMYCIN; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TAZAROTENE; TESTOSTERONE; UNINDEXED DRUG; VITAMIN B GROUP;

ACNE; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HYPERANDROGENISM; INFLAMMATION; NONHUMAN; ORGANIC DEPRESSION; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PREVALENCE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; REMISSION; REVIEW; RISK FACTOR; SEBACEOUS GLAND; SEBUM SECRETION; SIDE EFFECT; SKIN DUCT CORNIFICATION; SUICIDAL BEHAVIOR; SUICIDE;

ACNE VULGARIS; ANTI-INFECTIVE AGENTS; CONTRACEPTIVES, ORAL; DRUG RESISTANCE, BACTERIAL; HUMANS; PROPIONIBACTERIUM ACNES; RETINOIDS;

EID: 0041669322     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310016463     Document Type: Review

References (68)

1. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
2. Cunliffe WJ. Natural history of acne. In: Cunliffe WJ, ed. Acne. London: Martin Dunitz, 1989: 2-10.
3. Gollnick H, Zouboulis ChC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991; 18: 489-499.
4. Harris HH, Downing DT, Stewart ME, Strauss JS. Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol 1983; 8: 200-203.
5. Bläuer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol 1991; 97: 264-268.
6. Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localisation of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133: 467-475.
7. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase iso-enzyme expression. J Clin Invest 1993; 92: 903-910.
8. Luu-The V, Sugimoto Y, Puy L, Labrie Y, Lopez-Solache I, Singh M, et al. Characterization, expression, and immunohistochemical localization of 5-α-reductase in human skin. J Invest Dermatol 1994; 102: 221-226.
9. Thíboutot D, Harris G, Iles V, Címis G, Gílliland K, Hagari S. Activity of the type I 5 α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105: 209-214.
10. Chen WC, Zouboulis ChC, Orfanos CE. The 5 α-reductase system and its inhibitors: recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-184.
11. Zouboulis CC, Seltmann H, Hiroi N, Chen WC, Young M, Oeff M, et al. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. www.pnas.org/cgi/doi/10.1073
12. Weeks JG, McCarty L, Black T, Fulton JE. The inability of bacterial lipase inhibitor to control acne vulgaris. J Invest Dermatol 1977; 69: 236-243.
13. Downing DT, Stewart ME, Wertz PW, Strauss JS. Essential fatty acids and acne. J Am Acad Dermatol 1986; 14: 221-225.
14. Zouboulis C. Update on sebaceous gland physiology: induction of inflammation and its clinical implications. JEADV 2001; 15 Suppl. 2: 102.
15. Guy R, Kealey T. Modelling in acne. Dermatology 1998; 196: 32-37.
16. Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ. Pro-inflammatory levels of interleukin-1α-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992; 98: 895-901.
17. Eller MS, Yaar M, Ostrom K, Harkness DD, Gilchrest BA. A role for interleukin-1 in epidermal differentiation: regulation by expression of functional versus decoy receptors. J Cell Sci 1995; 108: 2741.
18. Akamatsu H, Horio T. The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology 1998; 196: 82-85.
19. Marples RR, McGinley KJ. Corynebacterium acnes and other anaerobic diphtheroids from human skin. J Med Microbiol 1974; 7: 349-357.
20. Holland KT. Microbiology of acne. In: Cunliffe WJ, ed. Acne. London: Martin Dunitz, 1989: 178-210.
21. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Age related changes in the resident bacterial flora of the human face. J Invest Dermatol 1975; 65: 379-381.
22. McGinley KJ. Regional variations in the density of cutaneous propionibacteria: correlation of Propionibacterium acnes populations with sebaceous secretions. J Clin Microbiol 1980; 12: 672-675.
23. Eady EA, Ingham E. Propionibacterium acnes- friend or foe. Rev Med Microbiol 1994; 5: 163-173.
24. Webster GF, Leyden JJ, Musson RA, Douglas SD. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun 1985; 49: 116-121.
25. Kirschbaum JD, Kligman AM. The pathogenic role of Corynebacterium acnes in acne vulgaris. Arch Dermatol 1963; 88: 832-833.
26. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin-resistant propionibacteria in antibiotic-treated acne patients. Association with therapeutic failure. Br J Dermatol 1989; 121: 51-57.
27. Holland KT, Holland DB, Cunliffe WJ, Cutcliffe AG. Detection of Propionibacterium acnes polypeptides which have stimulated an immune response in acne patients but not in normal individuals. Exp Dermatol 1993; 2: 12-16.
28. Ashbee HR, Muir SR, Cunliffe WJ, Ingham E. IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris. Br J Dermatol 1997; 136: 730-733.
29. Layton AM, Morris C, Cunliffe WJ, Ingham E. Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Exp Dermatol 1998; 7: 191-197.
30. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium acnes and inflammation in acne. P. acnes has T-cell-mitogenic activity. Br J Dermatol 2002; 146: 202-209.
31. Leyden JJ. Antibiotic resistant acne. Curtis 1976; 17: 593-596.
32. Crawford WW, Crawford IP, Stoughton RB, Cornell RC. Laboratory induction and clinical occurrence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979; 72: 187-190.
33. Ross JI, Carnegie E, Snelling AM, Coates P, Cove JH, Eady EA, et al. Prevalence of antibiotic resistant propionibacteria on the skin of acne patients from six European countries. JEADV 2001; 15 Suppl. 2: 135.
34. Cunliffe WJ. Propionibacterium acnes resistance and its clinical relevance. J Dermatol Treatment 1995; 6 Suppl. 1: S3-S4.
35. Dreno B, Reynaud A, Moyse D, Habert H, Richet H. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549-553.
36. Coates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840-848.
37. Nishijima S, Kurokawa I, Katoh N, Watanabe K. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. J Dermatol 2000; 27: 318-323.
38. Jaffe HW, Sweeney HM, Nathan C, Weinstein RA, Kabins SA, Cohen S. Identity and interspecific transfer of gentamicin-resistance plasmids in Staphylococcus aureus and Staphylococcus epidermidis. J Infect Dis 1980; 141: 738-747.
39. Mills O, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three month of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260-265.
40. Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 1996; 38: 829-837.
41. Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, et al. Phenotypic and genotypic characterisation of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001; 144: 339-346.
42. Ross JI, Eady EA, Carnegie E, Cove JH. Detection of transposons Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002; 49: 165-170.
43. Schaefer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145: 100-104.
44. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris. A disease of Western civilization. Arch Dermatol 2002; 138: 1584-1590.
45. Gollnick HPM. Guidelines "Acne and acne variants". Hautarzt 2002; 53: 322-327.
46. Tsukada M, Schröder M, Roos TC, Chandraratna RAS, Reichert U, Merk HF, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoic acid receptors. J Invest Dermatol 2000; 115: 321-327.
47. Camisa C, Eisenstat B, Ragaz A, Weissmann G. The effects of retinoids on neutrophil functions in vitro. J Am Acad Dermatol 1982; 6: 620-629.
48. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998; 39: S17-S24.
49. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol 2001; 45 Suppl. 1: 68-75.
50. Ng CH, Schweitzer I. The association between depression and isotretinoin use in acne. Aust NZ J Psychiatry 2003; 37: 78-84.
51. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001; 45: 196-207.
52. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. JEADV 2001; 15 Suppl. 3: 43-49.
53. Plewig G, Schöpf E. Anti-inflammatory effects of antimicrobial agents: an in-vivo study. J Invest Dermatol 1975; 65: 532-536.
54. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51-55.
55. Fulton JE, Pablo G. Topical antibacterial therapy for acne. Study of the family of erythromycins. Arch Dermatol 1974; 110: 83-86.
56. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol 1981; 104: 453-457.
57. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis 2001; 67: 21-24.
58. Holland KT, Bojar RA. Antimicrobial effects of azelaic acid. J Dermatol Treat 1993; 4 Suppl. 1: S8-11.
59. Pechere M, Germanier L, Siegenthaler G, Pechere JC, Saurat JH. The antibacterial activity of topical retinoids: the case of retinaldehyde. Dermatology 2002; 205: 153-158.
60. Ellis CN, Leyden J, Katz HI, Goldfarb MT, Hickman J, Jones TM et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67 Suppl. 2: 13-20.
61. Pfannschmidt N, Bauer R, Kreysel HW. Combined topical treatment of acne with erythromycin and tretinoin. Z Hautkr 1998; 63: 366-368.
62. Leyden JJ. Topical treatment for acne vulgaris. N Engl J Med 1997; 336: 1156-1162.
63. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. JEADV 2001; 15 Suppl. 3: 51-55.
64. Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998; 8: 161-168.
65. Zouboulis CC, Nestoris S, Adler YD, Picardo M, Camera E, Orth M, et al. Treatment of inflammatory acne with an oral lipoxygenase inhibitor. J Invest Dermatol 2001; 117: 547.
66. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002; 146: 178-188.
67. Niedre W. Oral antigen treatment (oral vaccination) in acne diseases. Z Allgemeinmed 1975; 20: 227-228.
68. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196: 59-66.